NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Borealis Biosciences

Borealis Biosciences

Private
VancouverHealthcare & Life Scienceshttps://www.borealisbio.com/

Last Round

Series A

Extension

Dec 19, 2024

Total Funding Raised

$210M

Company Overview

Borealis Biosciences is a biotechnology company that develops next-generation xRNA-based medicines for kidney diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

RNA therapeuticskidney diseasenephrologydrug discoverybiotech startupRNA medicinetranslational biologybuild-to-buytherapeutic developmentbiopharmadrug pipelinestealth biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Borealis Biosciences Comparables

Compare Borealis Biosciences with similar companies based on industry and business-model similarity.

Borealis Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Judo Bio
84%
Purespring Therapeutics
83%
Zeal Therapeutics, Inc.
82%

Borealis Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionDec 19, 2024
Series AAug 22, 2024

Key People

Founding team and executive leadership

Christian Hordo

Chief Executive Officer

Executive Team

Borealis Biosciences Investors

Notable investors and investment history

Borealis Biosciences investors
InvestorRounds
Westlake Village BioPartnersSeries A, Series A Extension
Versant VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2023

    Predecessor Chinook Therapeutics acquired by Novartis for $3.5B.

Borealis Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Borealis Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Borealis Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersVancouver
Employee Range55
Year Founded2024
Last FundingDec 19, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.